Table 3.
Prognostic variables for overall survival in the metastatic setting. mOS, Median overall survival
| Prognostic Variable | Number of Patients |
mOS (95% C.I) Months |
p-Value |
|---|---|---|---|
| Histopathology | |||
| Adenocarcinoma | 107 | 20.2 (16.1–26.7) | p < 0.001 |
| Mucinous Adenocarcinoma | 7 | 15.8 (NA) | |
| Signet cells | 5 | 7.0 (NA) | |
| Location of Primary | |||
| Left | 90 | 22.5 (16.2–27.7) | p = 0.18 |
| Right | 33 | 15.9 (9.0–22.0) | |
| KRAS Status * | |||
| Mutant | 32 | 18.5 (11.7–26.2) | p = 0.38 |
| Wild Type | 56 | 22.6 (17.1–28.8) | |
| BRAF Status ** | |||
| Mutant | 7 | 17.1 (NA) | p = 0.45 |
| Wild Type | 34 | 23.2 (16.0–46.5) |
Legend: p-value refers to log rank test; * In 35 patient KRAS status was unknown; ** In 82 patients BRAF status was unknown.